Dale J. Murdoch
Interventional cardiologist, St. Paul's Hospital, Vancouver · St. Paul's Hospital, University of British Columbia
These results further support the indication for percutaneous MV repair in patients with primary MR who are at high risk for surgery, accepting that patients treated commercially are different to those enrolled in EVEREST II—they are older, are more frail, and have higher surgical risk estimates.
Initial Experience With Commercial Transcatheter Mitral Valve Repair in the United States
Journal of the American College of CardiologySorajja et al.








